Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
Globe Newswire•04/11/2026•09:00 ET
0
Key Highlights
- ➤19 ASH 2026 abstracts accepted, including 7 revumenib oral presentations
- ➤14 revumenib abstracts span frontline, post-transplant, MRD relapse, and real-world settings
- ➤Frontline studies report remission, MRD negativity, and encouraging survival with revumenib combinations
- ➤5 axatilimab abstracts include long-term efficacy, safety, and treatment-duration data
- ➤Syndax schedules ASH investor event and webcast for December 14, 2026
Expert Statements
Nick Botwood, Head of Research & Development and Chief Medical Officer at Syndax
“The breadth of data accepted for presentation at ASH highlights our scientific leadership in menin and CSF-1R inhibition and deep commitment to advancing the standard of care for menin-dependent acute leukemias and chronic GVHD”
Nick Botwood, Head of Research & Development and Chief Medical Officer at Syndax
“Across fourteen revumenib abstracts, including seven oral presentations, we will highlight the growing body of clinical trial and real-world data showing compelling revumenib activity spanning the acute leukemia treatment continuum and multiple genetic subtypes.”
Nick Botwood, Head of Research & Development and Chief Medical Officer at Syndax
“We particularly look forward to the presentation of updated frontline data from the BEAT AML, SAVE, and 708 trials showing high rates of remission, MRD negativity, and encouraging survival among patients treated with revumenib in combination with standard of care therapies.”
Nick Botwood, Head of Research & Development and Chief Medical Officer at Syndax
“These results bolster our confidence that the ongoing pivotal frontline trials of revumenib-based combinations could transform outcomes for newly diagnosed NPM1m or KMT2Ar AML.”
– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax’s scientific leadership in menin inhibition –
– Revumenib abstracts highlight encouraging activity across multiple acute leukemia subtypes and settings, including frontline, post-transplant maintenance, and MRD relapse –
Get started
Create a free account to read the full story.